Literature DB >> 17164037

Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm.

Richard J Roman1, Marija Renic, Kathryn M J Dunn, Kazuhiko Takeuchi, Lotfi Hacein-Bey.   

Abstract

Recent studies have indicated that arachidonic acid (AA) is metabolized by the cytochrome P450 4A (CYP4A) enzymes in cerebral arteries to produce 20-hydroxyeicosatetraenoic acid (20-HETE) and that this compound has effects on cerebral vascular tone that mimic those seen following subarachnoid hemorrhage (SAH). In this regard, 20-HETE is a potent constrictor of cerebral arteries that decreases the open state probability of Ca(2+)-activated K(+) channels through activation of protein kinase C (PKC). It increases the sensitivity of the contractile apparatus to Ca(2+) by activating PKC and rho kinase. The formation of 20-HETE is stimulated by angiotensin II (AII), endothelin, adenosine triphosphate (ATP) and serotonin, and inhibited by NO, CO and superoxide radicals. Inhibitors of the formation of 20-HETE block the myogenic response of cerebral arterioles to elevations in transmural pressure in vitro and autoregulation of cerebral blood flow (CBF) in vivo. 20-HETE also plays an important role in modulating the cerebral vascular responses to vasodilators (NO and CO) and vasoconstrictors (AII, endothelin, serotonin). Recent studies have indicated that the levels of 20-HETE in cerebrospinal fluid (CSF) increase in rats, dogs and human patients following SAH and that inhibitors of the synthesis of 20-HETE prevent the acute fall in CBF in rats and reverse delayed vasospasm in both dogs and rats. This review examines the evidence that an elevation in the production of 20-HETE contributes to the initial fall in CBF following SAH and the later development of delayed vasospasm.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164037     DOI: 10.1179/016164106X152016

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  29 in total

Review 1.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

2.  Administration of a 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor Improves Outcome in a Rat Model of Pediatric Traumatic Brain Injury.

Authors:  Shiyu Shu; Zhi Zhang; Dawn Spicer; Ewa Kulikowicz; Ke Hu; Savalan Babapoor-Farrokhran; Sujatha Kannan; Raymond C Koehler; Courtney L Robertson
Journal:  Dev Neurosci       Date:  2019-09-25       Impact factor: 2.984

Review 3.  Vascular plasticity in cerebrovascular disorders.

Authors:  Lars I H Edvinsson; Gro Klitgaard Povlsen
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

4.  Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics.

Authors:  Zhongli Wang; Amit Singh Yadav; Wendy Leskova; Norman R Harris
Journal:  Exp Eye Res       Date:  2011-05-30       Impact factor: 3.467

Review 5.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

Review 6.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

7.  Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage.

Authors:  Elizabeth A Crago; Bhavani P Thampatty; Paula R Sherwood; Chie-Wen J Kuo; Catherine Bender; Jeffrey Balzer; Michael Horowitz; Samuel M Poloyac
Journal:  Stroke       Date:  2011-05-26       Impact factor: 7.914

Review 8.  Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought.

Authors:  Ryszard M Pluta; Jacob Hansen-Schwartz; Jens Dreier; Peter Vajkoczy; R Loch Macdonald; Shigeru Nishizawa; Hideotoshi Kasuya; George Wellman; Emanuela Keller; Alois Zauner; Nicholas Dorsch; Joseph Clark; Shigeki Ono; Talat Kiris; Peter Leroux; John H Zhang
Journal:  Neurol Res       Date:  2009-03       Impact factor: 2.448

9.  Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.

Authors:  Yi Zhang; Md Nasrul Hoda; Xuan Zheng; Weiguo Li; Pengcheng Luo; Krishna Rao Maddipati; Tsugio Seki; Adviye Ergul; Mong-Heng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

Review 10.  Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.

Authors:  Hui Huang; Mohamed Al-Shabrawey; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-12-30       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.